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ABSTRACT
Background. Bone morphogenetic proteins (BMPs) are
secreted signaling molecules belonging to the transforming
growth factor-b (TGF-b) superfamily of growth factors.
Recent studies have shown that the inﬂuence of the
expression of BMP7 was altered in several tumors. The
purpose of the current study was to examine the expression
of BMP7 in esophageal squamous cell carcinoma and to
clarify the clinical impact of BMP7 expression in esopha-
geal squamous cell carcinoma (ESCC).
Methods. A total of 180 patients with ESCC who under-
went surgical resection from 1991 to 2004 were eligible for
this study. The expression of BMP7 in esophageal tumor
tissues was examined immunohistochemically.
Results. BMP7 expression was found in the cytoplasm of
cancer cells. BMP7 positivity was observed in 61.7% of
tumors. The BMP7-positive group had deeper progression,
more advanced stages, and greater venous invasion than
those without BMP7 expression (p\0.001, p\0.005,
and p\0.0005, respectively). In addition, expression of
BMP7 correlated with poorer prognosis (p\0.0005).
Multivariate analysis showed that BMP7 expression status
was an independent prognostic factor (p\0.05).
Conclusions. Patients with expression of BMP7 in ESCC
had high malignant potential. BMP7 could be a useful
prognostic marker for patients with ESCC.
Esophageal squamous cell carcinoma (ESCC) is
aggressive in gastrointestinal tract carcinomas. Even when
patients with ESCC undergo curative resection, postoper-
ative relapse often occurs. Attempts to evaluate the group
at high risk of recurrence have been made in respect to
tumor aggressiveness. The tumor behavior of ESCC at the
molecular level has been intensively analyzed.
Among the molecular factors available for possible
evaluation of tumor aggressiveness, bone morphogenetic
protein (BMP) is a member of the transforming growth
factor (TGF)-b superfamily known to regulate cell prolif-
eration, apoptosis, and differentiation during human
development.
1,2 BMPs bind cell membrane type I and type
II receptors of serine/threonine kinases, eliciting intracel-
lular signaling via Smad1, 5, 8, and 9 proteins.
3,4 Recent
studies have shown that BMP7 maintains epithelial and
endothelial phenotypes against epithelial-mesenchymal
transition (EMT).
5,6
BMP7 is present in cancers, including breast, prostate,
and colon cancers, in which it is implicated in regulating
cancer cell proliferation.
7–9 Overexpression of BMP7
mRNA in colorectal cancer patients was signiﬁcantly
associated with poor prognosis and low overall survival.
10
However, the expression of BMP7 in ESCC has not been
evaluated.
In the present study, the BMP7 expression in surgical
specimens of ESCC was examined to evaluate whether this
molecule is useful to predict postoperative outcome.
MATERIALS AND METHODS
Patients and Specimens
There were 180 patients diagnosed with ESCC
(163 males and 17 females) who underwent R0
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1991 and 2004 at Kagoshima University Hospital, Kag-
oshima, Japan. The median age of the patients was 65.2
(range, 39–84) years.
None of these patients underwent endoscopic mucosal
resection, preoperative chemotherapy or radiotherapy, or
had metachronous multiple cancer in other organs. Speci-
mens of cancer tissue and noncancerous adjacent tissue
were collected from patients after informed consent had
been obtained in accordance with the institutional guide-
lines of our hospital. Using TNM classiﬁcation of the
International Union Against Cancer,
11 all of the M1 tumors
exhibited distant lymph node metastases. All patients were
followed-up after discharge, with x-ray examination and
tumor marker assays (squamous cell carcinoma antigen and
carcinoembryonic antigen) performed every 1 to 3 months,
computed tomography every 3 to 6 months, and ultraso-
nography every 6 months. Bronchoscopy and endoscopy
were performed if necessary.
Postoperative follow-up data were obtained from all
patients, with a median follow-up period of 39 (range,
1–137) months. According to TNM classiﬁcation, 74 of
the 180 patients had T1 tumors, 25 patients had T2
tumors, 78 patients had T3 tumors, and 3 patients had T4
tumors.
Immunohistochemical Staining and Evaluation
of BMP7 in ESCC
Tumor samples were ﬁxed with 10% formaldehyde in
phosphate-buffered saline (PBS), embedded in parafﬁn,
and sectioned into 4-lm-thick slices. They were deparaff-
inized in xylene and dehydrated with a series of graded
ethanol. The endogenous peroxidase activity of specimens
was blocked by immersing the slides in a 3% hydrogen
peroxidase-methanol solution for 10 min at room temper-
ature. After washing three times with PBS for 5 min each,
the sections were treated with 1% bovine serum albumin
for 30 min to block nonspeciﬁc reactions at room tem-
perature. Then, the sections were incubated with primary
antibody to BMP7 (1:200 R&D System) at 4C overnight
and subsequently stained with secondary antibodies for
30 min. The sections were incubated with avidin–biotin
complex for 60 min, and reactions were visualized using
diaminobenzidine tetrahydrochloride for 2 min. The sec-
tions were rinsed brieﬂy in water and counterstained with
hematoxylin for 30 s. Normal human kidney was used as a
positive (medullary rays) and negative (glomeruli) control
to verify both BMP7 antibody speciﬁcity and staining
quality (Fig. 1a).
12 Immunohistochemistry was indepen-
dently evaluated by two investigators (KM and SI) who
FIG. 1 Normal kidney section as a positive control for BMP7
staining. a BMP7 expression was seen in medullary rays and not seen
in glomeruli (9200). Expression of BMP7 in ESCCs. b Negative
expression of BMP7 (9200). c Positive expression of BMP7 was
detectable in cytoplasm and membranes (9200). Scale bar 100 lm
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cases in which the immunohistochemical evaluation of the
two observers differed, slides were evaluated by a third
observer (SN).
To evaluate the expression of BMP7, ten ﬁelds (within
the tumor and at the invasive front) were selected and
expression in 1,000 tumor cells (100 cells/ﬁeld) was eval-
uated using high-power (9200) microscopy. Expression of
BMP7 was assessed using the proportion of positive cells
and using intensity. At ﬁrst, we classiﬁed each sample into
one of three categories in terms of the proportion of posi-
tive cells: 1?, 0–29%; 2?, 30–59%; and 3?, C60%
positive cells. In addition, we classiﬁed each sample into
one of three categories according to the intensity: 1?,
weak; 2?, moderate; and 3?, strong. The tumors with
strong staining at least 30% of the cells and moderate
staining at least 60% of the cells were considered BMP7-
positive. We used this evaluation because of the hetero-
geneity of the ESCC samples and the fact that the deeper
the tumors invaded, the stronger their intensity tended to
become. We improved the evaluation method used by Liu
et al.
13
Statistical Analysis
Statistical analysis of group differences was performed
using the v
2 test. The Kaplan-Meier method was used for
survival analysis, and differences in survival were esti-
mated by using the log-rank test. Prognostic factors were
examined by univariate and multivariate analyses (Cox
proportional hazards regression model). A p value \0.05
was considered to indicate statistical signiﬁcance. All sta-
tistical analyses were performed using the StatView for
Windows software (Version 5.0, Abacus Concepts,
Berkeley, CA).
RESULTS
BMP7 Expression of ESCC
BMP7 expression was identiﬁed in cellular membrane
and cytoplasm of ESCC and was detected rarely in normal
esophageal epithelium. Positivity of BMP7 expression was
seen in 111 (61.7%) of 180 patients (Fig. 1c).
Relationship Between BMP7 Expression
and Clinicopathological Features
High-intensity BMP7 expression was detected more at
deeper areas in ESCC. The correlations between BMP7
expressionandclinicopathologicalcharacteristicsareshown
in Table 1. The BMP7-positive group had signiﬁcantly
deeper tumor invasion (p\0.001), more advanced stages
(p = 0.0012), more venous invasion (p = 0.0002), and
more locoregional recurrence (p = 0.027) than the BMP7-
negative group. We had 23 locoregional recurrences dur-
ing the period of this study: 3 were surgical anastomosis
recurrences, and 20 were lymph node recurrences. Further-
more, we examined the relationship between BMP7
expression and locoregional recurrence; 19 of 23 patients
with locoregionalrecurrencehad BMP7-positiveexpression
(Table 2).
TABLE 1 Relationship between BMP7 expression and clinicopath-
ologic ﬁndings
BMP7 expression p
(-)
n = 69
(?)
n = 111
Total (N = 180)
Age (mean ± SD) 64.6 ± 9 65.6 ± 9 0.975
Gender
Male 65 98 0.178
Female 4 13
Histology
Well 19 36 0.588
Moderate 34 53
Poor 9 22
p
T
T1 36 23 \0.0001
T2, T3, T4 33 88
p
N
N0 34 43 0.171
N1 35 68
p
M
M0 55 78 0.06
M1 14 33
Lymphatic invasion
Negative 24 24 0.052
Positive 45 87
Venous invasion
Negative 40 33 0.0002
Positive 29 78
Stage
I 20 13 0.0012
IIA, IIB 25 28
III 10 37
IV 14 33
Locoregional recurrence
Negative 65 4 0.027
Positive 92 19
SD standard deviation
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The 5-year overall survival rate was signiﬁcantly lower
in patients with BMP7-positive expression than in those
with negative expression (p = 0.0004; Fig. 2a). In 77
patients who had no lymph node metastasis, 43 patients
with BMP7-positive expression also had signiﬁcantly
lower 5-year overall survival rate than that of patients
judged to have BMP7-negative expression (p = 0.0016;
Fig. 2b).
Univariate and Multivariate Analysis of Survival
Table 3 shows the results of univariate and multivariate
analyses of the factors related to patient prognosis. Uni-
variate regression analyses revealed that depth of tumor
invasion, lymph node metastasis, pM status (distant lymph
node metastasis), venous invasion, locoregional recurrence,
and BMP7 expression signiﬁcantly affected postoperative
outcome. Multivariate analysis indicated that BMP7
expression was one of the independent prognostic factors
(p = 0.046), along with the depth of invasion (p = 0.019),
and pM status (distant lymph node metastasis) (p = 0.009;
Table 3).
DISCUSSION
This is the ﬁrst report to show an association between
BMP7 expression and clinicopathological ﬁndings in
ESCC. BMP7 positivity was observed in 61.7% of ESCC
tumors, which was a higher incidence than in colorectal
(41%) and breast cancers (46%).
10,14
BMP7 expression have been reported to be involved in
the growth of several cancer cells, such as osteosarcoma,
malignant melanoma, prostate cancer, breast cancer, renal
cell cancer, colorectal cancer, and gastric cancer, causing
increased aggression or suppression.
10,15–20 We showed
that BMP7 expression in ESCC was signiﬁcantly associ-
ated with the tumor depth, stages, and venous invasion.
Motoyama et al. investigated BMP7 mRNA in colorectal
cancer and showed its signiﬁcant association with tumor
extension and liver metastasis.
10 Aoki et al. reported
immunohistochemical expression of BMP7 in gastric can-
cer was signiﬁcantly related to the depth of tumors, nodal
involvement, lymphatic invasion, and venous invasion.
20
Those ﬁndings agree with our results. In this context,
cancerous BMP7 positivity may reﬂect tumor
aggressiveness.
In contrast, Kwak et al. reported that cancerous BMP7
expression correlated with better surgical outcome in renal
cell carcinoma.
15 Renal cells are used as a positive control
of BMP7 expression; this contradictory ﬁnding supports
organ-speciﬁcity. Aoki et al. also reported that BMP7
expression in gastric cancer was signiﬁcantly higher in the
well- and moderately differentiated histological group than
in the poorly differentiated histological group. In contrast,
in this study, we showed no relationship between BMP7
expression and tumor histological type; this contradictory
ﬁndings supports tumor-speciﬁcity (histologic differences
between squamous cell carcinoma and adenocarcinoma).
TABLE 2 Relationship between immunohistochemical staining for
BMP7 expression and locoregional recurrence
Recurrence site Total BMP7 expression
Positive
(n = 19)
Negative
(n = 4)
Lymph nodes 20 17 (85%) 3 (15%)
Surgical anastomosis 3 2 (66%) 1 (33%)
100
80
60
40
20
BMP7 ( −)
BMP7 (+)
6 0
Years after operation
a
Survival
rate (%) P = 0.0004
100
80
60
40
20
BMP7 ( −)
BMP7 (+)
6 0
Years after operation
b
Survival
rate (%) P = 0.0016
12345 12345
FIG. 2 a Overall 5-year
survival curves of patients with
esophageal cancer according to
the expression of BMP7.
Patients who were positive for
BMP7 expression exhibited
signiﬁcantly poorer prognosis
than those negative for BMP7
expression. b Overall 5-year
survival curves of patients
without lymph node metastasis
in relation to BMP7 expression.
Patients who were positive for
BMP7 expression exhibited
signiﬁcantly poorer prognosis
than those negative for BMP7
expression
Clinicopathological Signiﬁcance of BMP7 Expression in ESCC 2069BMP7 expression by immunohistochemistry was sig-
niﬁcantly associated with lower recurrence-free survival in
malignant melanoma and breast cancer.
14,17 Our recent
study showed BMP7 expression was signiﬁcantly related to
the locoregional recurrence. Those who had BMP7
expression tended to occur local lymph node relapse. Those
ﬁndings might have important clinical signiﬁcance. To
determinate BMP7 expression status in primary ESCC
could help to identify patients who are at high risk to
develop early local lymph node recurrence.
In vitro, the BMP7 signaling pathway in malignant
tumors has not been fully understood. From our results, in
ESCC, these speciﬁc signals for BMP7 may correspond
with tumor invasion in those signals that BMP7 stimulates.
In many cancers, TGF-b is a protumorigenic factor that
stimulates EMT.
21–23 In contrast, BMP7 is a strong inducer
of the reverse process (mesenchymal-epithelial transition;
MET) during embryonic development.
24–26 Moreover,
BMP7 can inhibit TGF-b-induced ﬁbrosis and counteracts
TGF-b-induced EMT in normal renal epithelial cells.
27–29
In contrast, in this study, overexpression of BMP7 in ESCC
was signiﬁcantly related to tumor aggressiveness. BMP7
might be related to tumor migration ability in ESCC. We
need to ﬁnd out more details about the cross-talk between
BMP7 and TGF-b signaling pathways in the context of
EMT.
As a prognostic parameter, Aoki et al. reported that
immunohistochemical BMP7 expression in gastric cancer
patients was associated with poor overall survival.
20
Moreover, overexpression of BMP7 mRNA was signiﬁ-
cantly associated with lower overall survival in colorectal
cancer.
10
In this study, concerning the overall survival analysis,
tumor depth, lymph node metastasis, venous invasion,
distant lymph node metastasis, locoregional recurrence,
and BMP7 expression were prognostic factors on univari-
ate analysis. We showed that BMP7 expression was one of
independent prognostic factors, along with tumor depth,
and distant lymph node metastasis on multivariate analysis
in accordance with results for other digestive tract cancers.
BMP7 expression could be used as a useful prognostic
parameter predicting the survival of postoperative ESCC
patients.
Various molecular markers have been shown to be
associated with development and progression of ESCC,
including cyclin D1, smad4, Fas, cyclin B1, CD151, Bmi-
1, and osteopontin.
13,30–35 Naitoh et al. demonstrated that
the survival rate for the patients with overexpression of
cyclin D1 was very low even in the patients without lymph
node metastasis.
30 In this study, the 5-year overall survival
rate for the patients with BMP7 positive expression was
signiﬁcantly worse than those with negative expression
even in the patients without lymph node metastasis. BMP7
expression may be a useful marker for high-risk patients of
ESCC without lymph node metastasis. This enables us to
choose postoperative treatment, including chemotherapy.
Moreover, we showed that BMP7 expression tends to
correlate with lymphatic invasion (p = 0.052). Thus, can-
cerous BMP7 expression in a biopsy may be informative to
predict lymphatic invasion. When selecting whether to
perform endoscopic resection for early ESCC, we can use
cancerous BMP7 expression as a predictor of lymphatic
invasion.
In conclusion, BMP7 expression in ESCC plays a crit-
ical role in tumor proliferation and invasion. Expression of
BMP7 may be a predictor of poor overall survival. This
independent molecular marker for high-risk patients could
help us in our attempts to individualize patients’ therapy.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
REFERENCES
1. Patel SR, Dressler GR. BMP7 signaling in renal development and
disease. Trends Mol Med. 2005;11:512–8.
2. Milan M. Sculpting a ﬂy leg: BMP boundaries and cell death. Nat
Cell Biol. 2007;9:17–8.
3. Attisano L, Wrana JL. Signal transduction by the TGF-beta
superfamily. Science. 2002;296:1646–7.
TABLE 3 Univariate and multivariate analysis of prognostic factors in ESCC
Factors Univariate analysis
p
Multivariate analysis
p Hazard ratio 95% CI
pT (1/2,3,4) (negative/positive) \0.0001* 0.019* 1.89 1.107–3.225
pN (negative/positive) 0.0003* 0.377 1.269 0.748–2.15
Venous invasion (negative/positive) 0.006* 0.622 1.121 0.71–1.769
pM (negative/positive) \0.0001* 0.009* 1.93 1.177–3.164
Locoregional recurrence (negative/positive) 0.03* 0.587 1.162 0.673–2.008
BMP7 expression 0.0004* 0.046* 1.61 1.008–2.576
* p\0.05
2070 K. Megumi et al.4. Massague J, Seoane J, Wotton D. Smad transcription factors.
Genes Dev. 2005;19:2783–810.
5. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative
regulator of epithelial homeostasis in the human prostate, is a
potent inhibitor of prostate cancer bone metastasis in vivo. Am J
Pathol. 2007;171:1047–57.
6. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-
mesenchymal transition contributes to cardiac ﬁbrosis. Nature.
2007;13:952–61.
7. Alamo EL, Rauta J, Kallioniemi A, et al. Bone morphogenetic
protein 7 is widely overexpressed in primary breast cancer. Genes
Chromosomes Cancer. 2006;45:411–9.
8. Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals
inhibit proliferation and in vivo tumor growth of androgen-
insensitive prostate carcinoma cells. Oncogene. 2004;23:
9326–35.
9. Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM. BMP-
induced growth suppression in colon cancer cells is mediated by
p21(WAF1) stabilization and modulated by RAS/ERK. Cell
Signal. 2007;19:1465–72.
10. Motoyama K, Tanaka F, Kosaka Y, et al. Clinical signiﬁcance of
BMP7 in human colorectal cancer. Ann Surg Oncol. 2008;15:
1530–36.
11. Sobin LH, Fleming ID. TNM classiﬁcation of malignant tumors.
5th ed. Union Internationale Contre le Cancer and the American
Joint Committee on Cancer. Cancer. 1997;80:1803–4.
12. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone mor-
phogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol.
2001;12:2392–9.
13. Liu WI, Guo XZ, Zeng MS, et al. Prognostic relevance of Bmi-1
expression and autoantibodies in esophageal squamous cell car-
cinoma. BMC Cancer. 2010;10:467.
14. Alarmo EL, Korhonen T, Huhtala H, et al. Bone morphogenetic
protein 7 expression associates with bone metastasis in breast
carcinomas. Ann Oncol. 2008;19:308–14.
15. Kwak C, Park YH, Kim IY, et al. Expression of bone morpho-
genetic proteins, the subfamily of the transforming growth factor-
b superfamily, in renal cell carcinoma. J Urol. 2007;178:1062–7.
16. Sulzbacher I, Birner P, Lang S, et al. The expression of bone
morphogenetic proteins in osteosarcoma and its relevance as a
prognostic parameter. J Clin Pathol. 2002;55:381–5.
17. Rothhammer T, Wild PJ, Bosserhoff AK, et al. Bone morpho-
genetic protein 7 (BMP7) expression is a potential novel
prognostic marker for recurrence in patients with primary mela-
noma. Cancer Biomark. 2007;3:111-7.
18. Masuda H, Hukabori Y, Yamanaka H, et al. Expression of bone
morphogenetic protein-7 (BMp-7) in human prostate. Prostate.
2004;59:101–6.
19. Alamo EL, Rauta J, Kallioniemi A, et al. Bone morphogenetic
protein 7 is widely overexpressed in primary breast cancer. Genes
Chromosomes Cancer. 2006;45:411–9.
20. Aoki M, Ishigami S, Natugoe S, et al. Expression of BMP-7 in
human gastric cancer and its clinical signiﬁcance. Br J Cancer.
2011;104:714–8.
21. Thiery JP. Epithelial-mesenchymal transitions in tumour pro-
gression. Nat Rev Cancer. 2002;2:442–54.
22. Peinado H, Quintanilla M, Cano A. Transforming growth factor
beta-1 induces snail transcription factor in epithelial cell lines:
mechanisms for epithelial mesenchymal transitions. J Biol Chem.
2003;278:21113–23.
23. Piek E, Moustakas A, Kurisaki A, et al. TGF-(beta) type I
receptor/ALK-5 and Smad proteins mediate epithelial to mesen-
chymal transdifferentiation in NMuMG breast epithelial cells.
J Cell Sci. 1999;112:4557–68.
24. Dudley AT, Lyons KM, Robertson EJ. A requirement for bone
morphogenetic protein-7 during development of the mammalian
kidney and eye. Genes Dev. 1995;9:2795–807.
25. Luo G, Hofmann C, Bronckers AL, et al. BMP-7 is an inducer of
nephrogenesis, and is also required for eye development and
skeletal patterning. Genes Dev. 1995;9:2808–20.
26. Vukicevic S, Kopp JB, Luyten FP, et al. Induction of nephrogenic
mesenchyme by osteogenic protein 1 (bone morphogenetic pro-
tein 7). Proc Natl Acad Sci U S A 1996;93:9021–6.
27. Simic P, Vukicevic S. Bone morphogenetic proteins in devel-
opment and homeostasis of kidney. Cytokine Growth Factor Rev.
2005;16:299–308.
28. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta-dependent
ﬁbrogenesis in mesangial cells. Am J Physiol Renal Physiol.
2003;284:F1006–13.
29. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-
beta1-induced epithelial-to-mesenchymal transition and reverses
chronic renal injury. Nature. 2003;9:964–8.
30. Naitoh H, Shibata J, Hattori T, et al. Overexpression and local-
ization of cyclin D1 mRNA and antigen in esophageal cancer. Am
J Pathol. 1995;5:1161–9.
31. Natsugoe S, Xiangming C, Aikou T, et al. Smad4 and trans-
forming growth factor b1 expression in patients with squamous
cell carcinoma of the esophagus. Clin Cancer Res. 2002;8:
1838–42.
32. Chan KW, Lee PY, Srivastava G, et al. Clinical relevance of Fas
expression in oesophageal squamous cell carcinoma. J Clin
Pathol. 2006;59:101–4.
33. Takeno S, Noguchi T, M} uller W, et al. Prognostic value of cyclin
B1 in patients with esophageal squamous cell carcinoma. Cancer.
2002;94:2874–81.
34. Suzuki S, Miyazaki T, Kuwano H, et al. Prognostic signiﬁcance
of CD151 expression in esophageal squamous cell carcinoma
with aggressive cell proliferation and invasiveness. Ann Surg
Oncol. 2011;18:888–93.
35. Kita Y, Natsugoe S, Aikou T, et al. Expression of osteopontin in
oesophageal squamous cell carcinoma. Br J Cancer. 2006;95:
634–8.
Clinicopathological Signiﬁcance of BMP7 Expression in ESCC 2071